Simon Rodriguez, MD
Nephrology · El Paso, TXNPI 1952512246
Payments from drug & device makers
Across 490 payments — averaging $3955.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$1.3M
- AstraZeneca$636K
- Takeda Pharmaceuticals U.S.A., Inc.$32K
- Biogen$12K
- Vifor Pharma, Inc.$1K
- Novo Nordisk$1K
- plus $5K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 8 | $1,250,170 |
| AstraZeneca(2 entities) | 72 | $636,002 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $32,471 |
| Biogen | 1 | $12,383 |
| Vifor Pharma, Inc. | 129 | $1,359 |
| Novo Nordisk | 15 | $1,047 |
| Amgen(2 entities) | 45 | $945 |
| Bayer | 38 | $680 |
| Travere Therapeutics, Inc. | 35 | $559 |
| Calliditas Therapeutics US Inc. | 17 | $369 |
| Otsuka America Pharmaceutical, Inc. | 21 | $350 |
| Boehringer Ingelheim | 16 | $285 |
| Akebia Therapeutics Inc | 22 | $273 |
| OPKO Pharmaceuticals, LLC | 13 | $237 |
| GSK | 11 | $215 |
| Aurinia Pharma U.S., Inc. | 10 | $195 |
| Ardelyx, Inc. | 8 | $193 |
| Medtronic | 1 | $114 |
| Fresenius USA Marketing, Inc. | 3 | $61 |
| Novartis | 3 | $59 |
| Veloxis Pharmaceuticals, Inc. | 1 | $35 |
| Pfizer | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Melinta Therapeutics, LLC | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Sanofi | 1 | $28 |
| Cormedix Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Nxstage Medical, Inc. | 1 | $13 |
| Outset Medical Inc | 1 | $10 |
How this compares
$1,938,324 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in El Paso
- German HernandezEl Paso$9.7M
- Pablo PergolaSan Antonio$14.2M
- Sreedhar MandayamHouston$7M
- Tahira AlvesSan Antonio$6.1M
- Carl DukesSan Antonio$5.9M
- Chinonye Ogbonnaya-OdorSan Antonio$4.6M
- Marializa BernardoHouston$4.2M
- Judith BettsAustin$3.7M
- Wesley CalhounSan Antonio$3.5M
- Adam FromeThe Woodlands$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.